1	4 subject take carbamazepine a monotherapy at baseline or who can be transfer to carbamazepine monotherapy in the two month before the screening visit dose of carbamazepine be within that recommend by the spc carbamazepine dose have not be alter during the previous 2 week prior to the start of the baseline|carbamazepine[15,28]|||||||||C0006949|2002|2002|carbamazepine
1	4 subject take carbamazepine a monotherapy at baseline or who can be transfer to carbamazepine monotherapy in the two month before the screening visit dose of carbamazepine be within that recommend by the spc carbamazepine dose have not be alter during the previous 2 week prior to the start of the baseline|carbamazepine[81,94]|||||||2 week[266,272]||C0006949|2002|2002|carbamazepine
1	4 subject take carbamazepine a monotherapy at baseline or who can be transfer to carbamazepine monotherapy in the two month before the screening visit dose of carbamazepine be within that recommend by the spc carbamazepine dose have not be alter during the previous 2 week prior to the start of the baseline|carbamazepine[159,172]|||||||two month[114,123]||C0006949|2002|2002|carbamazepine
1	4 subject take carbamazepine a monotherapy at baseline or who can be transfer to carbamazepine monotherapy in the two month before the screening visit dose of carbamazepine be within that recommend by the spc carbamazepine dose have not be alter during the previous 2 week prior to the start of the baseline|carbamazepine[209,222]|||||||||C0006949|2002|2002|carbamazepine
2	period or 6 week if the baseline period be to be shorten due to the availability of a retrospective seizure history the carbamazepine dose be to remain stable throughout the study|carbamazepine[428,441]|||||||6 week[318,324]||C0006949|2002|2002|carbamazepine
